Abstract
The chemical structure of selegiline, a commercially available drug for Parkinsons disease (PD), resembles that of 1,2,3,4-tetrahydroisoquinoline (TIQ), an endogenous parkinsonism-inducing compound. In the present study, we evaluated the direct cytotoxicity of (R)- and (S)-3-methyl-TIQ (3-MeTIQ) and (R)- and (S)-3-methyl-N-propargyl-TIQ (3- Me-N-propargyl-TIQ), as selegiline-mimetic TIQ derivatives, and their ability to prevent 1-methyl-4-phenylpyridinium iodide (MPP+)-induced cell death. Synthesis of optically-pure 3-MeTIQs was achieved via the super acid-induced cyclization of chiral N-benzyl-N-[1-methyl-2-(phenylsulfinyl)ethyl]formamide using a Pummerer-type cyclization reaction as the key step in producing excellent yields. Subsequent N-propargylation of chiral 3-MeTIQs using propynylbromide gave the corresponding 3-Me-N-propargyl-TIQs. In our in vitro experiments, the direct cytotoxicity of chiral 3-MeTIQs and 3-Me- N-propargyl-TIQs was almost identical, with no relationship to optical chirality except for (S)-3-Me-N-propargyl-TIQ, which had significantly weaker direct cytotoxicity than the other 3-MeTIQ derivatives. However, the decreased viability of PC12 cells induced by treatment with MPP+ was accelerated by the coexistence of 3-MeTIQs and inhibited by 3-Me-Npropargyl- TIQs without any participation of the stereochemistry at the 3-postion. These results suggest that the Npropargyl group is necessary for protection of cells against the toxicity of MPP+. Furthermore, the stereochemistry of the 3-position appears to partially participate in the direct cytotoxicity of 3-Me-N-propargyl-TIQs.
Keywords: 1,2,3,4-tetrahydroisoquinoline, selegiline, structure-activity relationships, cytotoxicity, Parkinson's disease
Medicinal Chemistry
Title: Synthesis of Chiral 3-Methyl- and 3-Methyl-N-propargyl-1,2,3,4- tetrahydroisoquinoline and Prevention of MPP+-Induced Cytotoxicity
Volume: 4 Issue: 6
Author(s): Toshiaki Saitoh, Aki Yamashita, Kenji Abe, Keita Ogawa, Michikazu Kitabatake, Kyoji Taguchi and Yoshie Horiguchi
Affiliation:
Keywords: 1,2,3,4-tetrahydroisoquinoline, selegiline, structure-activity relationships, cytotoxicity, Parkinson's disease
Abstract: The chemical structure of selegiline, a commercially available drug for Parkinsons disease (PD), resembles that of 1,2,3,4-tetrahydroisoquinoline (TIQ), an endogenous parkinsonism-inducing compound. In the present study, we evaluated the direct cytotoxicity of (R)- and (S)-3-methyl-TIQ (3-MeTIQ) and (R)- and (S)-3-methyl-N-propargyl-TIQ (3- Me-N-propargyl-TIQ), as selegiline-mimetic TIQ derivatives, and their ability to prevent 1-methyl-4-phenylpyridinium iodide (MPP+)-induced cell death. Synthesis of optically-pure 3-MeTIQs was achieved via the super acid-induced cyclization of chiral N-benzyl-N-[1-methyl-2-(phenylsulfinyl)ethyl]formamide using a Pummerer-type cyclization reaction as the key step in producing excellent yields. Subsequent N-propargylation of chiral 3-MeTIQs using propynylbromide gave the corresponding 3-Me-N-propargyl-TIQs. In our in vitro experiments, the direct cytotoxicity of chiral 3-MeTIQs and 3-Me- N-propargyl-TIQs was almost identical, with no relationship to optical chirality except for (S)-3-Me-N-propargyl-TIQ, which had significantly weaker direct cytotoxicity than the other 3-MeTIQ derivatives. However, the decreased viability of PC12 cells induced by treatment with MPP+ was accelerated by the coexistence of 3-MeTIQs and inhibited by 3-Me-Npropargyl- TIQs without any participation of the stereochemistry at the 3-postion. These results suggest that the Npropargyl group is necessary for protection of cells against the toxicity of MPP+. Furthermore, the stereochemistry of the 3-position appears to partially participate in the direct cytotoxicity of 3-Me-N-propargyl-TIQs.
Export Options
About this article
Cite this article as:
Saitoh Toshiaki, Yamashita Aki, Abe Kenji, Ogawa Keita, Kitabatake Michikazu, Taguchi Kyoji and Horiguchi Yoshie, Synthesis of Chiral 3-Methyl- and 3-Methyl-N-propargyl-1,2,3,4- tetrahydroisoquinoline and Prevention of MPP+-Induced Cytotoxicity, Medicinal Chemistry 2008; 4 (6) . https://dx.doi.org/10.2174/157340608786242043
DOI https://dx.doi.org/10.2174/157340608786242043 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
Call for Papers in Thematic Issues
Carbohydrates in Computational and Medicinal Chemistry
Carbohydrates are the most essential organic molecules and are involved in the maintenance of various physiological and metabolic processes in living organisms. Carbohydrate-based compounds have come to the attention of researchers because of their significant contributions to biological functions, such as cell development and cell proliferation, connections between several cells, ...read more
Recent Advances in the Medicinal Chemistry of Cancer
Scope of the Thematic Issue: Correlation between structure and function is one of the important aspects of the success of anti-cancer compounds associated with their structure-activity interactions, physiology, biochemical, molecular, and genetic processes. Overcoming these obstacles is key to obtaining further insights into developments in rational drug design, bioorganic chemistry, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting SKCa Channels in Cancer: Potential New Therapeutic Approaches
Current Medicinal Chemistry Natural Products Containing Olefinic Bond: Important Substrates for Semi-synthetic Modification Towards Value Addition
Current Organic Chemistry The Cannabinoid 2 Receptor as a Potential Therapeutic Target for Sepsis
Endocrine, Metabolic & Immune Disorders - Drug Targets Immunotherapy in Liver Diseases: A Balance Between Immunity and Tolerance
Current Drug Metabolism N-Terminal Microdomain Peptide from Human Dihydroorotate Dehydrogenase: Structure and Model Membrane Interactions
Protein & Peptide Letters Editorial [Hot Topic: Metabotropic Glutamate Receptors: Medicinal Chemistry and Therapeutic Implications (Guest Editor: Craig W. Lindsley)]
Current Topics in Medicinal Chemistry Anti-Depressant
Current Bioactive Compounds Heme Oxygenase-1 as a Therapeutic Target in Neurodegenerative Diseases and Brain Infections
Current Pharmaceutical Design NAD+ Metabolism and NAD+-Dependent Enzymes: Promising Therapeutic Targets for Neurological Diseases
Current Drug Targets Sex and Gender Differences in the Brain Cholinergic System and in the Response to Therapy of Alzheimer Disease with Cholinesterase Inhibitors
Current Alzheimer Research Cow’s Milk Allergy: Where have we Come from and where are we Going?
Endocrine, Metabolic & Immune Disorders - Drug Targets Antidepressant Brain Stimulation Techniques
Current Psychiatry Reviews Recent Developments in the Regulation of Monoamine Oxidase Form and Function: Is the Current Model Restricting Our Understanding of the Breadth of Contribution of Monoamine Oxidase to Brain [dys]Function?
Current Topics in Medicinal Chemistry Paullones as Inhibitors of Protein Kinases
Current Topics in Medicinal Chemistry Genetic Lipodystrophies: Models for Insulin Resistance
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Are Cerebral Perfusion and Atrophy Linked in Multiple Sclerosis? Evidence for a Multifactorial Approach to Assess Neurodegeneration
Current Neurovascular Research Cordycepin Exerts Neuroprotective Effects via an Anti-Apoptotic Mechanism based on the Mitochondrial Pathway in a Rotenone-Induced Parkinsonism Rat Model
CNS & Neurological Disorders - Drug Targets Pharmacology of Cell Adhesion Molecules of the Nervous System
Current Neuropharmacology Repetitive Ritalin Treatment Modulates the Diurnal Activity Pattern of Young SD Male Rats
Central Nervous System Agents in Medicinal Chemistry Incidence of Profound Hypogammaglobulinemia and Infection Rate in Lymphoma Patients Following the Combination of Chemotherapy and Rituximab
Recent Patents on Anti-Cancer Drug Discovery